tetano
Editor, Senior Moderator
Clin Infect Dis
. 2021 Jul 10;ciab625.
doi: 10.1093/cid/ciab625. Online ahead of print.
Reducing influenza virus transmission: the value of antiviral treatment
Frederick G Hayden[SUP] 1 [/SUP], Jason Asher[SUP] 2 [/SUP], Benjamin J Cowling[SUP] 3 [/SUP], Aeron C Hurt[SUP] 4 [/SUP], Hideyuki Ikematsu[SUP] 5 [/SUP], Klaus Kuhlbusch[SUP] 4 [/SUP], Annabelle Lemenuel-Diot[SUP] 4 [/SUP], Zhanwei Du[SUP] 3 [/SUP], Lauren Ancel Meyers[SUP] 6 [/SUP], Pedro A Piedra[SUP] 7 [/SUP], Takahiro Takazono[SUP] 8 [/SUP], Hui-Ling Yen[SUP] 3 [/SUP], Arnold S Monto[SUP] 9 [/SUP]
Affiliations
Abstract
Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication following antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients appears to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modelling studies indicate that early treatment would have major epidemiologic benefits in seasonal and pandemic influenza.
Keywords: antiviral; baloxavir; influenza; oseltamivir; transmission.
. 2021 Jul 10;ciab625.
doi: 10.1093/cid/ciab625. Online ahead of print.
Reducing influenza virus transmission: the value of antiviral treatment
Frederick G Hayden[SUP] 1 [/SUP], Jason Asher[SUP] 2 [/SUP], Benjamin J Cowling[SUP] 3 [/SUP], Aeron C Hurt[SUP] 4 [/SUP], Hideyuki Ikematsu[SUP] 5 [/SUP], Klaus Kuhlbusch[SUP] 4 [/SUP], Annabelle Lemenuel-Diot[SUP] 4 [/SUP], Zhanwei Du[SUP] 3 [/SUP], Lauren Ancel Meyers[SUP] 6 [/SUP], Pedro A Piedra[SUP] 7 [/SUP], Takahiro Takazono[SUP] 8 [/SUP], Hui-Ling Yen[SUP] 3 [/SUP], Arnold S Monto[SUP] 9 [/SUP]
Affiliations
- PMID: 34245250
- DOI: 10.1093/cid/ciab625
Abstract
Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication following antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients appears to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modelling studies indicate that early treatment would have major epidemiologic benefits in seasonal and pandemic influenza.
Keywords: antiviral; baloxavir; influenza; oseltamivir; transmission.